Skip to main content
. 2022 Sep 2;13:980464. doi: 10.3389/fimmu.2022.980464

Table 1.

Characteristics of patient and donor.

Characteristics N=80
Median age, year (range) 28 (14-56)
Gender, n (%)
 Male 42 (52.50)
 Female 38 (47.50)
Disease, n (%)
 AML 37 (46.25)
 ALL 38 (47.50)
 MDS 5 (6.25)
Risk stratification, n (%)
AML/MDS
 Intermediate 18 (42.86)
 High 24 (57.14)
ALL
 Standard 14 (36.84)
 High 24 (63.16)
Median time from diagnosis to HSCT, months (range) 6.0 (0.3-36.0)
Median follow-up time, months (range) 22.4 (2.5-57.8)
Disease status, n (%)
AML/MDS
 CR1 26 (61.90)
 CR≥2 13 (30.95)
 Non-CR 3 (7.15)
ALL
 CR1 23 (60.53)
 CR≥2 14 (36.84)
 Non-CR 1 (2.63)
MRD
 Negative 73 (96.25)
 Positive 7 (3.75)
Donor-recipient sex match, n (%)
 Male-male 29 (36.25)
 Male-female 26 (32.50)
 Female-male 16 (20.00)
 Female-female 9 (11.25)
Donor-recipient blood match, n (%)
 Matched 53 (66.25)
 Major mismatched 13 (16.25)
 Minor mismatched 14 (17.50)
HLA compatibility of, n (%)
PB
 5/10 45 (56.25)
 6/10 23 (28.75)
 7/10 5 (6.25)
 8/10 5 (6.25)
 9/10 2 (2.50)
UCB
 6/10 7 (8.75)
 7/10 17 (21.25)
 8/10 32 (41.25)
 9/10 19 (23.75)
 10/10 4 (5.00)
 Median PB MNC, ×108/kg (range) 10.50 (4.63-19.30)
 Median PB CD34+ cells, ×10 6/kg (range) 5.68 (1.61-14.12)
 UCB MNC, ×10 7/kg 1
 UCB CD34+ cells, ×10 4/kg 3.42 (1.12-13.56)

AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; HSCT, hemopoietic stem cell transplantation; CR, complete remission; PB, peripheral blood; UCB, unrelated cord-blood.